Particle Sciences Manufactures Clinical Supplies for Kinex’s Glioblastoma Therapeutic

Particle Sciences, Inc. (PSI), has completed the manufacturing of clinical supplies for the first in human studies of KX2-361 (KX02), Kinex Pharmaceuticals’ small molecule Src/pre-tublin inhibitor. According to Bruce Frank, Vice President of Project Management at PSI, "PSI’s business has grown to a great degree on the strength of our expanding cGMP manufacturing capabilities. We have worked hard to build a reputation around quality and responsiveness and are excited to help Kinex get this very important drug into the clinic." PSI is a leading CDMO with a focus on highly potent compounds and complex formulations.

"Kinex’s selection of Particle Sciences to help advance this key product into the clinic was based on their excellent reputation, quality of their people, as well as the responsiveness and focus of their organization. I am very proud to say that Particle Sciences has exceeded our expectations and remains a key partner in Kinex’s product development program" commented Mark Seep, Clinical Manufacturing Manager for Kinex Pharmaceuticals, Inc.

"We are pleased that Particle Sciences collaborated with Kinex to manufacture a formulation of KX2-361 for our first in human clinical studies. We are expecting KX2-361 to help address the important unmet medical need of treating brain cancers for the many patients that await therapeutic advances for this serious disease" remarked David Hangauer, Kinex’s Chief Scientific Officer.